Cargando…
A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19
Objective: Efficacy and safety of Itolizumab, an immunomodulatory mAb, in treating moderate-to-severe acute respiratory distress syndrome (ARDS) due to cytokine release in COVID-19 patients was evaluated in a multi-centric, open-label, two-arm, controlled, randomized, phase-2 study. Methods: Patient...
Autores principales: | Kumar, Suresh, De Souza, Rosemarie, Nadkar, Milind, Guleria, Randeep, Trikha, Anjan, Joshi, Shashank R., Loganathan, Subramanian, Vaidyanathan, Sivakumar, Marwah, Ashwani, Athalye, Sandeep N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040494/ https://www.ncbi.nlm.nih.gov/pubmed/33835886 http://dx.doi.org/10.1080/14712598.2021.1905794 |
Ejemplares similares
-
Itolizumab in Psoriasis
por: Srivastava, Ankita
Publicado: (2017) -
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin‐R with the US‐licensed Humulin® R formulation in healthy subjects: Results from the RHINE‐1 (Recombinant Human INsulin Equivalence‐1) study
por: Plum‐Mörschel, Leona, et al.
Publicado: (2022) -
Off-label Use of Itolizumab in Patients with COVID-19 ARDS: Our Clinical Experience in a Dedicated COVID Center
por: Kumari, Poonam, et al.
Publicado: (2021) -
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE‐3 (Recombinant Human
INsulin
Equivalence‐3) study
por: Plum‐Mörschel, Leona, et al.
Publicado: (2022) -
Paranephric air in COVID-ARDS patient: an extension of pneumothorax
por: Singh, Abhishek, et al.
Publicado: (2021)